Compositions and methods useful in enhancement of memory
View Patent ↗Compounds derived from a transduction complex that enhance memory in mammals and methods of enhancing memory using said compounds are disclosed.
1. A biologically active fusion peptide comprising:
an isolated first peptide having an amino acid sequence of SEQ ID NO: 2; and
an isolated second peptide consisting of amino acids 156-174 of SEQ ID NO: 3, wherein the second peptide is operably linked to the first peptide.
2. The peptide of claim 1 wherein the biologically active peptide is capable of translocating across a biological membrane.
3. The peptide of claim 1 further comprising a label.
4. The peptide of claim 3 , wherein the label is selected from the group consisting of radioisotopes, radionuclides, fluorescent labels, enzymatic labels, chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter, magnetic agents, toxins, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin.
5. The peptide of claim 3 wherein the label comprises a detectable label.
6. The peptide of claim 1 wherein the peptide comprises an amino acid sequence of SEQ ID NO: 1.
7. A method of enhancing memory in a subject comprising administering a first treatment modality comprising an effective amount of a first pharmaceutical composition comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1 to the subject.
8. The method of claim 7 wherein the first pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
9. The method of claim 7 wherein the subject is a mammal.
10. The method of claim 7 wherein the subject presents with memory loss.
11. The method of claim 7 further comprising the step of administering a second treatment modality to the subject.
12. The method of claim 11 wherein the second treatment modality comprises a second pharmaceutical composition.
13. The method of claim 12 wherein administering the second pharmaceutical composition is concurrent with administering the first pharmaceutical composition.
14. The method of claim 12 wherein the second pharmaceutical composition comprises a pharmaceutically acceptable carrier.
15. The method of claim 12 wherein administering the second pharmaceutical composition is subsequent to administering the first pharmaceutical composition.